Radiopharm Theranostics Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the month of April 2026 for Radiopharm Theranostics Limited, a foreign private issuer headquartered in Carlton South, Victoria, Australia. The filing reports on a specific corporate announcement made to the Australian Securities Exchange on April 7, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an informational filing regarding a corporate agreement and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the signing of a Clinical Supply Agreement between Radiopharm Theranostics (RAD) and Siemens for the product RAD101. No financial comparisons to prior periods are included in this document.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the partnership with Siemens. The filing does not provide specific financial guidance, discuss general risks, or detail contingencies beyond the scope of the attached Public Notice regarding the RAD101 supply agreement.
Investor Verification Checklist
- Verify the terms and duration of the Clinical Supply Agreement with Siemens for RAD101.
- Review the attached Exhibit 99.1 (Public Notice) for specific details on the agreement not summarized in the Form 6-K.
- Confirm the current development status and regulatory pathway of the RAD101 product.
- Check for subsequent filings that may provide financial impact analysis of this agreement.